Rosalind Advisors Inc. Increases Stock Position in PolyPid Ltd. (NASDAQ:PYPD)

Rosalind Advisors Inc. increased its position in PolyPid Ltd. (NASDAQ:PYPD) by 49.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,018,021 shares of the company’s stock after buying an additional 338,853 shares during the quarter. PolyPid comprises about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 19th biggest position. Rosalind Advisors Inc. owned 9.99% of PolyPid worth $3,095,000 at the end of the most recent reporting period.

Separately, AIGH Capital Management LLC grew its stake in PolyPid by 21.8% during the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after buying an additional 148,199 shares during the period. 26.47% of the stock is owned by institutional investors and hedge funds.

PolyPid Stock Performance

NASDAQ:PYPD opened at $2.81 on Friday. PolyPid Ltd. has a 1-year low of $2.37 and a 1-year high of $5.50. The stock has a market cap of $28.64 million, a P/E ratio of -0.57 and a beta of 1.27. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.31 and a quick ratio of 1.00. The firm has a 50-day moving average of $3.00 and a two-hundred day moving average of $3.21.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). On average, research analysts expect that PolyPid Ltd. will post -1.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PYPD has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on PolyPid in a report on Tuesday, January 28th. They set a “buy” rating and a $13.00 target price on the stock.

PolyPid Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.